- Home
- KOD vs HTO Comparison
KOD vs HTO Comparison
Compare KOD & HTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | HTO |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United States | United States |
| Employees | N/A | 837 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | HTO |
|---|---|---|
| Price | $45.52 | $59.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $35.43 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 1.1M | 516.8K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $7.06 |
| P/E Ratio | ★ N/A | $17.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $43.75 |
| 52 Week High | $47.84 | $61.87 |
Technical Indicators
Market Signals| Indicator | KOD | HTO |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 52.88 |
| Support Level | $21.82 | $55.80 |
| Resistance Level | $45.60 | $59.59 |
| Average True Range (ATR) | 3.11 | 1.66 |
| MACD | -0.39 | -0.06 |
| Stochastic Oscillator | 71.41 | 48.61 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.